Literature DB >> 16322420

Patient satisfaction with migraine management by family physicians.

Anne D Walling1, Douglas C Woolley, Craig Molgaard, K James Kallail.   

Abstract

Over 70% of the estimated 5 million office visits per year for migraine headache are to family physicians. Both the number of visits and proportion of migraine patients seeking medical care are increasing rapidly. Patient satisfaction with migraine care by primary care physicians is reported to be low but most data are obtained from patients referred to subspecialists or entered in clinical trials. We surveyed patients who consulted family physicians in 10 Kansas practices during 2002 to assess patient satisfaction and investigate any differences between satisfied and unsatisfied migraine patients. Of our 447 respondents, 74% were "satisfied" or "very satisfied" with migraine care by family physicians. Dissatisfied patients were significantly more likely to report moderate or severe migraine-related disability and less likely to use triptans or to have most medications paid by insurance. Dissatisfied patients were twice as likely to have discontinued taking triptans than satisfied patients. Patient satisfaction with migraine treatment in family practice is substantially higher than generally reported. Statistically significant differences exist between satisfied and dissatisfied patients.

Entities:  

Mesh:

Year:  2005        PMID: 16322420     DOI: 10.3122/jabfm.18.6.563

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  7 in total

Review 1.  Cognitive expertise, emotional development, and reflective capacity: clinical skills for improved pain care.

Authors:  Beth B Murinson; Aakash K Agarwal; Jennifer A Haythornthwaite
Journal:  J Pain       Date:  2008-11       Impact factor: 5.820

2.  A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).

Authors:  Roger K Cady; Peter J McAllister; Egilius L H Spierings; John Messina; Jennifer Carothers; Per G Djupesland; Ramy A Mahmoud
Journal:  Headache       Date:  2014-10-30       Impact factor: 5.887

3.  Quality of life and migraine disability among female migraine patients in a tertiary hospital in Malaysia.

Authors:  Munvar Miya Shaik; Norul Badriah Hassan; Huay Lin Tan; Siew Hua Gan
Journal:  Biomed Res Int       Date:  2015-01-08       Impact factor: 3.411

4.  A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.

Authors:  Sagar Munjal; Elimor Brand-Schieber; Kent Allenby; Egilius L H Spierings; Roger K Cady; Alan M Rapoport
Journal:  J Headache Pain       Date:  2017-03-01       Impact factor: 7.277

5.  DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.

Authors:  Richard B Lipton; Sagar Munjal; Elimor Brand-Schieber; Alan M Rapoport
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

6.  Patient satisfaction with computer-assisted structured initial assessment facilitating patient streaming to emergency departments and primary care practices: results from a cross-sectional observational study accompanying the DEMAND intervention in Germany.

Authors:  Ingmar Schäfer; Agata Menzel; Tobias Herrmann; Jan Hendrik Oltrogge; Dagmar Lühmann; Martin Scherer
Journal:  BMC Prim Care       Date:  2022-08-23

7.  Management of headache disorders: design of a randomised clinical trial screening for prognostic patient characteristics.

Authors:  Willem J De Hertogh; Peter H Vaes; Dirk Devroey; Steven Truijen; William Duquet; Rob Oostendorp
Journal:  BMC Musculoskelet Disord       Date:  2007-04-26       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.